Company profile: Fortrea
1.1 - Company Overview
Company description
- Provider of comprehensive Phase I-IV clinical trial management, clinical pharmacology, patient access solutions, and other enabling services for biopharma and medical device and diagnostic companies, including medical device and diagnostic development, global regulatory submissions, and protocol development.
Products and services
- Clinical Pharmacology: Offers human-subject services studying drug effects and mechanisms in humans, supporting drug development and therapeutics with clinically derived insights
- Patient Access Solutions: Supplies recruitment-focused programs improving patient access to clinical trials and therapies, enhancing enrollment and retention to strengthen study participation
- Phase I–IV Clinical Trial Management: Delivers end-to-end management for trials from Phase I through IV, covering the full spectrum of the clinical trial process.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Fortrea
Adalvo
HQ: Malta
Website
- Description: Provider of B2B pharmaceutical products and services, part of Alvogen Group and powered by Alvogen and Alvotech. Offers 90+ specialty generic small-molecule products across Oncology, Women’s Health, Cardiovascular and CNS; 15+ value-added 505(b)(2) CNS therapies; and 8+ peptide products for Rare Diseases and Diabetes. Develops Fidaxomicin 200 mg tablets, Ethinylestradiol/Drospirenone, and Dimethyl Fumarate for RRMS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adalvo company profile →
Vibalogics
HQ: Germany
Website
- Description: Provider of contract development and manufacturing services for live biological products, including process development, manufacturing and fill & finish for oncolytic viruses, gene therapies and vaccines. Capabilities span viral vector and live virus production, RNA and LNP manufacturing, plasmid development and manufacturing, upstream/downstream and formulation development, and cGMP manufacturing for phase 1–2 clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vibalogics company profile →
Liverpool ChiroChem
HQ: United Kingdom
Website
- Description: Provider of chiral small molecules for biotech/pharma R&D, offering specialist building blocks, fragments and screening compounds to enable small molecule drug discovery, plus ultra-large (1.4B), covalent (800k) and kinase-focused (4.5M) virtual libraries, DEL synthons, heterobifunctional linkers, and a parallel synthesis lab producing up to 5,000 compounds per month.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Liverpool ChiroChem company profile →
VintaBio
HQ: United States
Website
- Description: Provider of cell and gene therapy manufacturing services to pharmaceutical and biotechnology organizations to alleviate the viral vector bottleneck. Offerings include GMP manufacturing with integrated supply chain, process development and toxicology materials from cell line to drug product, research vector production, analytical assays for quality control and release, and CMC support for IND and pre-BLA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VintaBio company profile →
TransCure BioServices
HQ: Switzerland
Website
- Description: Provider of predictive preclinical R&D services via fee-for-service access to humanized mouse platforms, including CD34+ humanized immune system, humanized liver, immuno-oncology, IBD, inflammatory disorder, and infectious disease (HIV, HBV) models, used to profile new drugs and assess efficacy/toxicity, drug-drug interactions, immunotherapies, and antivirals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TransCure BioServices company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Fortrea
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fortrea
2.2 - Growth funds investing in similar companies to Fortrea
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Fortrea
4.2 - Public trading comparable groups for Fortrea
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →